CLEO DIAGNOSTICS ORD
CLEO Diagnostics Expands US Addressable Market for Pre-Surgical Ovarian Cancer Test
CLEO Diagnostics (ASX: COV) has used an analysis of insurance data to significantly expand the total addressable market in the US for its new pre-surgical ovarian cancer detection test.
Market wrap: late market rally not enough to erase midweek losses
A late rally on Friday wasn’t enough for the Australian share market to recover from ground lost earlier in the week. Despite climbing 0.96% or 73.5 points on Friday, the ASX 200 gave up 0.42% for the week. Inflation still high Australia’s annual consumer inflation rate accelerated to 3.6% in April 2024, its highest level […]
Study shows Cleo Diagnostics’ ovarian cancer blood test outperforms current clinical benchmark
A benchmarking study comparing Cleo Diagnostics’ (ASX: COV) novel blood test for the accurate and early detection of ovarian cancer against conventional ultrasound options has been published in the scientific journal Cancers. The study compared the blood test with current standard clinical workflows that use cancer antigen 125 (CA125) testing and ultrasound to predict malignancy. […]
Cleo Diagnostics IPO raises $12 million to develop early-stage detection blood test for ovarian cancer
A novel and patented simple blood test which aims to detect ovarian cancer accurately and early, is the cornerstone of a successful $12 million initial public offering by medical technology company Cleo Diagnostics (ASX: COV). The Melbourne-based business is focused on advancing its patented and licenced technology development activities after issuing 60 million shares at […]